...
首页> 外文期刊>Clinics and research in hepatology and gastroenterology >Histological differentiation predicts post-liver transplantation survival time
【24h】

Histological differentiation predicts post-liver transplantation survival time

机译:组织学差异预测肝移植后的存活时间

获取原文
获取原文并翻译 | 示例

摘要

Objectives: Although liver transplantation is the most effective long-term treatment for hepatocellular carcinoma (HCC), the recurrence of HCC remains an issue. Current research examining recurrence after liver transplantation primarily focuses on patients' clinical characteristics. There is no consensus regarding the factors that may relate to predict the survival time and recurrence rates for patients with hepatitis B virus (HBV)-associated HCC transplantation using clinicopathological analysis. Methods: One hundred and three patients with HCC were enrolled in the study. All data were collected from the China Liver Transplant Registry. The independent variables were as follows: age, gender, etiology, preoperative alpha-fetoprotein (AFP) levels, body mass index (BMI), Model for End-stage Liver Disease (MELD) and Child-Pugh scores, primary tumor, regional nodes, metastasis (TNM) classification, number of tumors, the size for the largest tumor, multifocality, portal vein tumor thrombosis and histological differentiation, and prognostic staging score criteria (Milan criteria). All of the patients had previously undergone liver transplantation. Univariate and multivariate analysis were used to determine the factors related to the survival time and recurrence. Results: After a median follow-up period of 41.05. ±. 28.90 months, the 5-year overall survival rate was 46.60%, and the 5-year recurrence rate was 45.63%. Forty-seven patients (45.63%) died due to HCC recurrence during the follow-up period. Patients within Milan criteria exhibited excellent post-transplantation survival times. Univariate analysis suggested that patients with poor tumor differentiation, AFP. ≥. 400. ng/ml, portal vein tumor thrombosis, and TNM staging of I. +. II had significantly predicted shorter survival times and higher recurrence than patients displaying good or moderate tumor differentiation, AFP. < 400. ng/ml, no portal vein thrombosis and TNM staging of III. +. IV for HBV-associated HCC. However, multivariate analysis revealed that poor tumor differentiation and high serum AFP were associated with a shorter survival time. Moreover, poor tumor differentiation suggested high recurrence. In addition, patients' survival time with AFP. < 400. ng/ml was longer than that of patients with AFP. ≥. 400. ng/ml even in patients with HCC beyond Milan criteria.
机译:目的:尽管肝移植是治疗肝细胞癌(HCC)的最有效的长期治疗方法,但HCC的复发仍是一个问题。目前研究肝移植后复发的研究主要集中在患者的临床特征上。对于使用临床病理分析预测与乙型肝炎病毒(HBV)相关的HCC移植患者的生存时间和复发率的因素,尚无共识。方法:103例HCC患者入选本研究。所有数据均从中国肝移植登记处收集。独立变量如下:年龄,性别,病因,术前甲胎蛋白(AFP)水平,体重指数(BMI),终末期肝病模型(MELD)和Child-Pugh评分,原发肿瘤,区域性淋巴结转移,转移(TNM)分类,肿瘤数量,最大肿瘤的大小,多灶性,门静脉肿瘤血栓形成和组织学分化以及预后分期标准(米兰标准)。所有患者以前都接受过肝移植。使用单因素和多因素分析来确定与生存时间和复发相关的因素。结果:中位随访期为41.05。 ±。 28.90个月,5年总生存率为46.60%,5年复发率为45.63%。在随访期间有47例患者(45.63%)因HCC复发而死亡。符合米兰标准的患者表现出出色的移植后生存时间。单因素分析提示,患者的肿瘤分化不良,AFP。 ≥。 400. ng / ml,门静脉肿瘤血栓形成和I. +的TNM分期。与具有良好或中度肿瘤分化的AFP患者相比,II具有显着的预测更短的生存时间和更高的复发率。 <400. ng / ml,无门静脉血栓形成和III期TNM分期。 +。乙肝相关肝癌的静脉注射。然而,多变量分析显示,不良的肿瘤分化和高血清AFP与较短的生存时间有关。此外,不良的肿瘤分化提示高复发。此外,使用AFP可以延长患者的生存时间。 <400. ng / ml比AFP患者更长。 ≥。甚至超过米兰标准的HCC患者也应达到400 ng / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号